Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Indication

Esophageal Squamous Cell Carcinoma

Clinical and regulatory intelligence for Esophageal Squamous Cell Carcinoma with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
2
Catalysts
0
Assets
2

Relevant assets

Lactobacillus →
Phase →

Relevant companies

oncology therapeutics →

Recent signals(2)

ClinicalJune 21, 2026

Lactobacillus reuteri promotes ferroptosis resistance in esophageal cancer via STAT3 lactylation

Lactobacillus reuteri induces D-lactate production, promoting STAT3 lactylation and reducing ferroptosis in ESCC.

ClinicalJune 19, 2026

Phase II Trial of ILDR Plus Immunochemotherapy in Borderline Resectable Esophageal Cancer

A phase II trial is set to evaluate the efficacy and safety of intestinal low-dose radiotherapy combined with immunochemotherapy in patients with borderline resectable or unresectable esophageal squamous cell carcinoma.

Upcoming catalysts

No catalysts indexed for this entity yet.

Therapeutic areas

Esophageal Squamous Cell Carcinoma →
Oncology →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.